Form 4: Helius Medical Technologies CFO Receives Stock Options

Jeffrey S. Mathiesen, CFO and Treasurer of Helius Medical Technologies, was granted stock options for 139,857 shares under the company's 2022 Equity Incentive Plan.

Summary

• Jeffrey S. Mathiesen, the CFO and Treasurer of Helius Medical Technologies, Inc., received a grant of stock options on January 6, 2025.
• The stock options are for 139,857 shares of Class A Common Stock.
• The exercise price of the options is $0.7292 per share.
• 50% of the options vested immediately, with the remainder vesting in equal quarterly installments over the next three years, starting March 31, 2025, contingent upon continued service.

Sentiment

Score: 7

Explanation: The document indicates standard executive compensation practices, which is generally viewed neutrally to positively as it aligns management with shareholder interests.

Positives

• The grant of stock options aligns the CFO's interests with those of the shareholders.
• The vesting schedule incentivizes continued service and contribution to the company's success.

Future Outlook

The vesting schedule of the stock options suggests an expectation of continued service by the CFO through the vesting period.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes management to improve company performance.
• The CFO is incentivized to remain with the company and contribute to its growth.

Key Dates

Keywords

stock options, Helius Medical Technologies, CFO, Jeffrey S. Mathiesen, equity incentive plan, Form 4, insider trading